Try our beta test site
1448 studies found for:    chronic myelogenous leukemia
Show Display Options
Rank Status Study
1 Completed
Has Results
Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response
Conditions: Philadelphia Chromosome Positive;   Chronic Myelogenous Leukemia in Chronic Phase
Intervention: Drug: Nilotinib
2 Recruiting Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Condition: Chronic Myelogenous Leukemia
Intervention: Other: Chart Review
3 Completed Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia
Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Nilotinib,Novartis,300 mg twice a day +Pegylated interferon 2a,Roche, 45 microg weekly starting Month 2-Month 12 or beyond according to investigator choice.
4 Terminated
Has Results
TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients
Condition: Chronic Myelogenous Leukemia
Interventions: Drug: Imatinib Mesylate (IM);   Drug: TALL-104 cells
5 Completed Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
Condition: Chronic Myelogenous Leukemia
Intervention: Drug: decitabine (5-aza-2'deoxycytidine)
6 Completed Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
Condition: Chronic Myelogenous Leukemia
Intervention: Drug: decitabine (5-aza-2'deoxycytidine)
7 Completed Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
Condition: Chronic Myelogenous Leukemia
Intervention: Drug: decitabine (5-aza-2'deoxycytidine)
8 Completed Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec
Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Nexavar (Sorafenib, BAY43-9006)
9 Completed Autologous Transplantation for Chronic Myelogenous Leukemia
Condition: Chronic Myelogenous Leukemia
Interventions: Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Imatinib Mesylate;   Procedure: Autologous Stem Cell Transplantation
10 Terminated Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia
Condition: Chronic Myelogenous Leukemia
Interventions: Drug: Zileuton (Zyflo®) Dasatinib (Sprycel®);   Drug: Dosing with Zileuton/Dasatinib in CML;   Drug: Daily dosing of Zileuton/Dasatinib;   Drug: Daily dosing with Zileuton/Dasatinib for CML
11 Completed Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib
Condition: Chronic Myelogenous Leukemia - Chronic Phase
Intervention: Drug: Nilotinib
12 Recruiting Regional Central Database Recording of Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Intervention: Other: Practices evaluation
13 Recruiting Bosutinib Dose-Optimization Study in Chronic Myeloid Leukemia (CML)
Condition: Chronic Myelogenous Leukemia
Interventions: Drug: Bosutinib;   Behavioral: Phone Calls;   Behavioral: Questionnaires
14 Completed Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia
Conditions: Chronic Myelomonocytic Leukemia;   Chronic Myelogenous Leukemia
Intervention: Drug: Imatinib
15 Completed
Has Results
Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
Condition: Chronic Myelogenous Leukemia
Interventions: Drug: imatinib mesilate;   Drug: interferon-alpha (INF-a);   Drug: cytarabine (ARA-C)
16 Completed Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase
Conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase Chronic Myelogenous Leukemia
Interventions: Drug: omacetaxine mepesuccinate;   Drug: cytarabine;   Other: laboratory biomarker analysis
17 Completed
Has Results
Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia
Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Dasatinib
18 Active, not recruiting Study of Dasatinib in Patients With Chronic Myelogenous Leukemia
Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Dasatinib (BMS-354825)
19 Completed Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)
Condition: Chronic Myelogenous Leukemia in Chronic Phase
Intervention: Drug: Imatinib
20 Completed Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
Conditions: Childhood Chronic Myelogenous Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase Chronic Myelogenous Leukemia
Interventions: Drug: imatinib mesylate;   Other: laboratory biomarker analysis;   Other: pharmacological study

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.